FDA approves blood indication for Sprycel

Today the FDA¬†approved a new indication for Bristol-Myers Squibb‘s Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.